New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity
Castle Biosciences, Inc. - Common stock (CSTL)
Last castle biosciences, inc. - common stock earnings: 3/10 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
FRIENDSWOOD, Texas, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating the clinical value of its DecisionDx-Melanoma test in improving sentinel lymph node (SLN) biopsy (SLNB) decision making and enhancing recurrence risk prediction in patients with cutaneous melanoma (CM). The data will be featured in two oral presentations at the 2nd European Congress on Dermato-Oncology (ECDO), taking place Nov. 17–18, 2025, in Paris, France. “DecisionDx-Melanoma continues to demonstrate strong performance in helping physicians make more informed, risk-aligned decisions about sentinel lymph node biopsy,” said J. Michael Guenther, M.D., presenting author for both studies and surgical oncologist at St. Elizabeth Physicians in Edgewood, Kentucky. “These new data reinforce how the test can accurately identify patients with a low likelihood of sentinel node positi
Show less
Read more
Impact Snapshot
Event Time:
CSTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CSTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CSTL alerts
High impacting Castle Biosciences, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
CSTL
News
- Does New Melanoma Data Redefine the Bull Case for Castle Biosciences' DecisionDx Platform (CSTL)? [Yahoo! Finance]Yahoo! Finance
- Castle Biosciences (NASDAQ:CSTL) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year [Yahoo! Finance]Yahoo! Finance
- Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive YearGlobeNewswire
- New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity [Yahoo! Finance]Yahoo! Finance
CSTL
Earnings
- 11/3/25 - Beat
CSTL
Sec Filings
- 12/4/25 - Form 4
- 12/1/25 - Form 4
- 11/26/25 - Form 4
- CSTL's page on the SEC website